Hangzhou Beiputai Biopharmaceutical Co., Ltd. was established in 2023. It is a high-tech enterprise focusing on the research and development and sales of peptides and related derivatives. The company currently has a peptide research and development center in the Overseas Students Pioneer Park in Qiantang District, Hangzhou. It has several well-equipped peptide research and development production lines and multiple sets of large-scale peptide synthesis and analysis equipment, including imported Agilent high-performance liquid phase analysis chromatographs, AB mass spectrometers, high-performance liquid chromatography preparation instruments and other equipment. The company's main scientific researchers have more than ten years of experience in peptide research and development and can meet the personalized customization requirements of different customers. At present, we can provide: GLP-1 peptides (semaglutide/telpotide/retalutide, etc.), small molecule analog peptides, FAPI, PSMA, OCT and other radioactive imaging peptide precursors (RDC precursors), PDC peptide compounds, peptide inhibitors (aldehyde peptides/FMK/CMK/AMOK, etc.), fluorescent enzyme substrates (PNA/AMC/AFC/R110, etc.), Ser-Thr glycopeptides, isotope-labeled peptides, macrocyclic peptides, MAPS composite antigen peptides, fluorescently labeled peptides, cell-penetrating peptides, etc., to meet the application needs of different customers. At present, the company has more than 1,000 mature peptide products, and the annual output of peptides can reach more than 30kg.